Project Grant R42DA041959

The U.S. National Institute on Drug Abuse (NIDA) awarded a $800,000 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Biosensics LLC for the development and clinical validation of ODALERT - a wearable device designed to automatically detect and alert users and first responders of opioid-induced respiratory arrest. The project aims to address the urgent public health issue of opioid overdoses by creating an innovative wearable technology solution. Key...

The National Institute on Drug Abuse (NIDA) awarded a $643,948 Project Grant under CFDA 93.279 (Drug Use and Addiction Research Programs) to Labsys LLC, a for-profit limited liability company located in East Lansing, Michigan. The grant, titled "Wearable Continuous Drug Monitoring Device for Personal Medications in Opioid Use Disorders (CDM-MOUD)," aims to develop a transformative wearable patch that can continuously monitor medication levels in individuals with opioid use disorders....

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $400,000 to Mountainpass Technology LLC to develop and evaluate a customized version of the "MyTrials" remote biomarker capture system for use in decentralized clinical trials (DCTs) for substance use disorders (SUDs). The key products and services to be delivered include: 1) Refinement of the existing MyTrials prototype to support the...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting the development of a software-based medical device (SAMD) for detecting opioid use through voice analysis. The $800,000 award to Tenvos Inc., a minority-owned and woman-owned technology company, aims to advance the company's AI-driven solution that can enable patients to remotely test for opioid use and securely share results with...

The National Institute on Drug Abuse (NIDA) awarded a $386,452 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant supports the development of a rapid fingerstick diagnostic for opioid and stimulant use disorders (OUD/STUD), which represent a significant public health crisis with over 107,000 overdose deaths reported in 2022. The project period runs from April 1, 2025, to...

This $586,936 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of a low-cost, disposable urine test strip that can rapidly and quantitatively measure substance use disorder (SUD) medication drugs and their metabolites. The award recipient, Vitan-Biotech LLC, will create a point-of-use lateral flow assay (LFA) test strip that leverages innovative signal amplification technology to...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) provides $318,257 to Cari Health, Inc. to develop a therapeutic monitoring system (TMS) for remote medication compliance tracking of methadone treatment for opioid use disorder (OUD). The key products and services to be delivered include: 1) Integrating an electrochemical sensor, microneedle array, and data pipeline into a prototype wearable...

The National Science Foundation (NSF) Division of Electrical, Communications and Cyber Systems awarded a $399,541 Project Grant to the Trustees of Dartmouth College to develop a high-throughput, label-free, and portable sensor that can quantitatively detect multiple illicit drugs including opioids, cocaine, psychostimulants, and methadone in liquid samples such as biofluids. The project aims to create a silver or gold nanoparticle-decorated zinc oxide nanorod coated silica nanofiber matrix...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $319,000 to Sano Healthcare Consultants, LLC for the development of a novel liquid methadone dispensing device and smart container system. The project aims to address key barriers in accessing medication for opioid use disorder (MOUD) by creating a low-cost, single-device solution that enables remote supervised use, telehealth, and behavioral...

The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $319,278 Project Grant to Photopharmics, Inc. to develop a novel, non-pharmacological Heterodyned Whole Body Vibration (HWBV) device to treat Opioid Use Disorder (OUD). This 1-year Phase I award supports: 1) technical improvements to the HWBV device, evaluation of physiological anxiety indices, and implementation of device telemetry; 2) assessment of blood catecholamines and...